Gain Therapeutics (GANX) Stock Forecast, Price Target & Predictions
GANX Stock Forecast
Gain Therapeutics stock forecast is as follows: an average price target of $7.00 (represents a 366.67% upside from GANX’s last price of $1.50) and a rating consensus of 'Buy', based on 14 wall street analysts offering a 1-year stock forecast.
GANX Price Target
The average price target for Gain Therapeutics (GANX) is $7.00 based on 1-year price targets from 14 Wall Street analysts in the past 3 months, with a price target range of $10.00 to $4.00. This represents a potential 366.67% upside from GANX's last price of $1.50.
GANX Analyst Ratings
According to 14 Wall Street analysts, Gain Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for GANX stock is 0 'Strong Buy' (0.00%), 12 'Buy' (85.71%), 1 'Hold' (7.14%), 1 'Sell' (7.14%), and 0 'Strong Sell' (0.00%).
Gain Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 09, 2022 | - | Chardan Capital | $4.00 | $3.15 | 26.98% | 166.67% |
| Nov 13, 2022 | Thomas Shrader | BTIG | $10.00 | $3.21 | 211.53% | 566.67% |
The latest Gain Therapeutics stock forecast, released on Dec 09, 2022 by Chardan Capital company, set a price target of $4.00, which represents a 26.98% increase from the stock price at the time of the forecast ($3.15), and a 166.67% increase from GANX last price ($1.50).
Gain Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $1.50 | $1.50 | $1.50 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Gain Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Gain Therapeutics's last price of $1.50. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 03, 2024 | Maxim Group | Buy | Buy | Hold |
| Sep 03, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jul 02, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 12, 2023 | Canaccord Genuity | - | Buy | Initialise |
| Sep 12, 2023 | Cowen & Co. | - | Outperform | Initialise |
| Sep 12, 2023 | Macquarie | - | Outperform | Initialise |
| Sep 12, 2023 | Seaport Global | - | Sell | Initialise |
| Sep 12, 2023 | RBC Capital | - | Outperform | Initialise |
| Sep 12, 2023 | Deutsche Bank | - | Buy | Initialise |
| Sep 12, 2023 | B. Riley Securities | Neutral | Buy | Initialise |
Gain Therapeutics's last stock rating was published by Maxim Group on Sep 03, 2024. The company gave GANX a "Buy" rating, the same as its previous rate.
Gain Therapeutics Financial Forecast
Gain Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | $55.18K | - | $95.10K | $45.01K | - | $15.97K | $5.27K |
| Avg Forecast | $50.00K | $50.00K | $50.00K | $50.00K | $33.33K | $10.00K | $400.00K | $120.00K | $250.00K | $337.50K | $1.01M | $10.00K | $51.50K | $31.67K | $39.00K | $51.60K | $20.00K | $4.96K |
| High Forecast | $50.00K | $50.00K | $50.00K | $50.00K | $33.33K | $10.00K | $400.00K | $120.00K | $250.00K | $337.50K | $1.01M | $10.00K | $51.50K | $31.67K | $39.00K | $51.60K | $20.00K | $5.96K |
| Low Forecast | $50.00K | $50.00K | $50.00K | $50.00K | $33.33K | $10.00K | $400.00K | $120.00K | $250.00K | $337.50K | $1.01M | $10.00K | $51.50K | $31.67K | $39.00K | $51.60K | $20.00K | $3.97K |
| # Analysts | 1 | 1 | 1 | 1 | 3 | 1 | - | 2 | 4 | 1 | - | - | - | - | 2 | 3 | 4 | 7 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 5.52% | - | 3.00% | 1.15% | - | 0.80% | 1.06% |
Gain Therapeutics's average Quarter revenue forecast for Jun 23 based on 0 analysts is $1.01M, with a low forecast of $1.01M, and a high forecast of $1.01M. GANX's average Quarter revenue forecast represents a 1725.16% increase compared to the company's last Quarter revenue of $55.18K (Mar 23).
Gain Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 3 | 1 | - | 2 | 4 | 1 | - | - | - | - | 2 | 3 | 4 | 7 |
| EBITDA | - | - | - | - | - | - | - | - | $-4.41M | $-4.89M | $-7.73M | $-5.19M | $-4.78M | $-5.22M | $-3.30M | - | $-4.65M | $-2.44M |
| Avg Forecast | $-50.00K | $-50.00K | $-50.00K | $-50.00K | $-33.33K | $-10.00K | $-400.00K | $-120.00K | $-250.00K | $-337.50K | $-1.01M | $-10.00K | $-5.02M | $-31.67K | $-4.06M | $-51.60K | $-20.00K | $-1.02M |
| High Forecast | $-50.00K | $-50.00K | $-50.00K | $-50.00K | $-33.33K | $-10.00K | $-400.00K | $-120.00K | $-250.00K | $-337.50K | $-1.01M | $-10.00K | $-4.02M | $-31.67K | $-3.25M | $-51.60K | $-20.00K | $-819.18K |
| Low Forecast | $-50.00K | $-50.00K | $-50.00K | $-50.00K | $-33.33K | $-10.00K | $-400.00K | $-120.00K | $-250.00K | $-337.50K | $-1.01M | $-10.00K | $-6.03M | $-31.67K | $-4.87M | $-51.60K | $-20.00K | $-1.23M |
| Surprise % | - | - | - | - | - | - | - | - | 17.63% | 14.47% | 7.68% | 518.69% | 0.95% | 164.73% | 0.81% | - | 232.71% | 2.39% |
undefined analysts predict GANX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Gain Therapeutics's previous annual EBITDA (undefined) of $NaN.
Gain Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 3 | 1 | - | 2 | 4 | 1 | - | - | - | - | 2 | 3 | 4 | 7 |
| Net Income | - | - | - | - | - | - | - | - | $-4.57M | $-4.72M | $-7.69M | $-5.14M | $-4.56M | $-5.09M | $-3.27M | - | $-4.66M | $-2.45M |
| Avg Forecast | $-3.55M | $-3.55M | $-3.65M | $-3.94M | $-3.93M | $-3.98M | $-3.74M | $-5.97M | $-6.00M | $-8.57M | $-5.92M | $-7.57M | $-5.03M | $-5.81M | $-4.07M | $-9.24M | $-6.82M | $-1.03M |
| High Forecast | $-3.55M | $-3.55M | $-3.65M | $-3.94M | $-3.93M | $-3.98M | $-3.74M | $-5.97M | $-5.62M | $-8.57M | $-5.92M | $-7.57M | $-4.03M | $-5.81M | $-3.25M | $-9.24M | $-6.82M | $-821.48K |
| Low Forecast | $-3.55M | $-3.55M | $-3.65M | $-3.94M | $-3.93M | $-3.98M | $-3.74M | $-5.97M | $-6.18M | $-8.57M | $-5.92M | $-7.57M | $-6.04M | $-5.81M | $-4.88M | $-9.24M | $-6.82M | $-1.23M |
| Surprise % | - | - | - | - | - | - | - | - | 0.76% | 0.55% | 1.30% | 0.68% | 0.91% | 0.87% | 0.80% | - | 0.68% | 2.39% |
Gain Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. GANX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Gain Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 3 | 1 | - | 2 | 4 | 1 | - | - | - | - | 2 | 3 | 4 | 7 |
| SG&A | - | - | - | - | - | - | - | - | $2.03M | $2.52M | $3.74M | $2.49M | $2.79M | $2.69M | $1.78M | - | $2.19M | $1.05M |
| Avg Forecast | $3.61M | $3.61M | $3.61M | $3.61M | $2.41M | $721.67K | $28.87M | $8.66M | $18.04M | $24.36M | $72.68M | $721.67K | $3.72M | $2.29M | $2.81M | $3.72M | $1.44M | $358.31K |
| High Forecast | $3.61M | $3.61M | $3.61M | $3.61M | $2.41M | $721.67K | $28.87M | $8.66M | $18.04M | $24.36M | $72.68M | $721.67K | $3.72M | $2.29M | $2.81M | $3.72M | $1.44M | $429.90K |
| Low Forecast | $3.61M | $3.61M | $3.61M | $3.61M | $2.41M | $721.67K | $28.87M | $8.66M | $18.04M | $24.36M | $72.68M | $721.67K | $3.72M | $2.29M | $2.81M | $3.72M | $1.44M | $286.57K |
| Surprise % | - | - | - | - | - | - | - | - | 0.11% | 0.10% | 0.05% | 3.46% | 0.75% | 1.18% | 0.63% | - | 1.51% | 2.93% |
Gain Therapeutics's average Quarter SG&A projection for Mar 24 is $8.66M, based on 2 Wall Street analysts, with a range of $8.66M to $8.66M. The forecast indicates a 325.92% rise compared to GANX last annual SG&A of $2.03M (Dec 23).
Gain Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 3 | 1 | - | 2 | 4 | 1 | - | - | - | - | 2 | 3 | 4 | 7 |
| EPS | - | - | - | - | - | - | - | - | $-0.29 | $-0.37 | $-0.62 | $-0.43 | $-0.38 | $-0.43 | $-0.28 | - | $-0.39 | $-0.50 |
| Avg Forecast | $-0.18 | $-0.18 | $-0.19 | $-0.20 | $-0.20 | $-0.21 | $-0.19 | $-0.31 | $-0.31 | $-0.45 | $-0.31 | $-0.39 | $-0.45 | $-0.30 | $-0.35 | $-0.48 | $-0.36 | $-0.32 |
| High Forecast | $-0.18 | $-0.18 | $-0.19 | $-0.20 | $-0.20 | $-0.21 | $-0.19 | $-0.31 | $-0.29 | $-0.45 | $-0.31 | $-0.39 | $-0.45 | $-0.30 | $-0.35 | $-0.48 | $-0.36 | $-0.32 |
| Low Forecast | $-0.18 | $-0.18 | $-0.19 | $-0.20 | $-0.20 | $-0.21 | $-0.19 | $-0.31 | $-0.32 | $-0.45 | $-0.31 | $-0.39 | $-0.45 | $-0.30 | $-0.35 | $-0.48 | $-0.36 | $-0.32 |
| Surprise % | - | - | - | - | - | - | - | - | 0.93% | 0.83% | 2.01% | 1.09% | 0.85% | 1.42% | 0.81% | - | 1.10% | 1.58% |
According to undefined Wall Street analysts, Gain Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to GANX previous annual EPS of $NaN (undefined).
Gain Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| INAB | IN8bio | $0.33 | $14.00 | 4142.42% | Buy |
| CUE | Cue Biopharma | $0.57 | $5.00 | 777.19% | Buy |
| LIFE | aTyr Pharma | $1.90 | $11.00 | 478.95% | Buy |
| MOLN | Molecular Partners | $5.08 | $29.00 | 470.87% | Buy |
| GANX | Gain Therapeutics | $1.50 | $7.00 | 366.67% | Buy |
| ANEB | Anebulo Pharmaceuticals | $2.27 | $6.00 | 164.32% | Buy |
| NAMS | NewAmsterdam Pharma Company | $15.45 | $36.00 | 133.01% | Buy |
| CELC | Celcuity | $14.98 | $31.50 | 110.28% | Buy |
| ELYM | Eliem Therapeutics | $7.96 | $13.00 | 63.32% | Buy |
| ELVN | Enliven Therapeutics | $21.47 | $33.00 | 53.70% | Buy |
| CYT | Cyteir Therapeutics | $3.02 | $2.00 | -33.77% | Sell |
GANX Forecast FAQ
Is Gain Therapeutics a good buy?
Yes, according to 14 Wall Street analysts, Gain Therapeutics (GANX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 12 'Buy' recommendations, accounting for 85.71% of GANX's total ratings.
What is GANX's price target?
Gain Therapeutics (GANX) average price target is $7 with a range of $4 to $10, implying a 366.67% from its last price of $1.5. The data is based on 14 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Gain Therapeutics stock go up soon?
According to Wall Street analysts' prediction for GANX stock, the company can go up by 366.67% (from the last price of $1.5 to the average price target of $7), up by 566.67% based on the highest stock price target, and up by 166.67% based on the lowest stock price target.
Can Gain Therapeutics stock reach $2?
GANX's average twelve months analyst stock price target of $7 supports the claim that Gain Therapeutics can reach $2 in the near future.
What are Gain Therapeutics's analysts' financial forecasts?
Gain Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $563.33K (high $563.33K, low $563.33K), average EBITDA is $-563K (high $-563K, low $-563K), average net income is $-17.63M (high $-17.63M, low $-17.63M), average SG&A $40.65M (high $40.65M, low $40.65M), and average EPS is $-0.917 (high $-0.917, low $-0.917). GANX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $200K (high $200K, low $200K), average EBITDA is $-200K (high $-200K, low $-200K), average net income is $-14.7M (high $-14.7M, low $-14.7M), average SG&A $14.43M (high $14.43M, low $14.43M), and average EPS is $-0.765 (high $-0.765, low $-0.765).
Did the GANX's actual financial results beat the analysts' financial forecasts?
Based on Gain Therapeutics's last annual report (Dec 2023), the company's revenue was $55.18K, which missed the average analysts forecast of $1.6M by -96.56%. Apple's EBITDA was $-22.253M, beating the average prediction of $-1.605M by 1286.81%. The company's net income was $-22.268M, missing the average estimation of $-28.052M by -20.62%. Apple's SG&A was $10.79M, missing the average forecast of $115.8M by -90.68%. Lastly, the company's EPS was $-1.71, beating the average prediction of $-1.46 by 17.13%. In terms of the last quarterly report (Mar 2023), Gain Therapeutics's revenue was $55.18K, beating the average analysts' forecast of $10K by 451.80%. The company's EBITDA was $-5.187M, beating the average prediction of $-10K by 51769.42%. Gain Therapeutics's net income was $-5.137M, missing the average estimation of $-7.57M by -32.14%. The company's SG&A was $2.49M, beating the average forecast of $721.67K by 245.55%. Lastly, the company's EPS was $-0.43, beating the average prediction of $-0.394 by 9.15%